Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MT 2766

Next Previous
Drug Profile

MT 2766

Alternative Names: Adjuvanted COVID-19 vaccine - Glaxosmithkline/Medicago; Coronavirus-like particle COVID-19 vaccine; COVID-2019 vaccine - Glaxosmithkline/ Medicago; COVIFENZ; CoVLP adjuvanted vaccine with AS03 adjuvant; GSK-4362620A; MT-2766; Plant-derived COVID-19 vaccine - Glaxosmithkline/Medicago; Recombinant coronavirus-like particle vaccine

Latest Information Update: 15 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline; Medicago
  • Developer Medicago; Mitsubishi Tanabe Pharma Corporation
  • Class COVID-19 vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered COVID 2019 infections

Most Recent Events

  • 02 Jun 2023 Medicago withdraws a phase III trial in COVID-2019 infections (Prevention, In adults) in Canada (IM) prior to enrolment (NCT05040789)
  • 07 Feb 2023 Medicago terminates a phase-I/II trial due to ethical reason so as to prioritise the ancestral vaccination in COVID-2019 infections (Prevention) in Japan (IM) (NCT05065619) (jRCT2051210093)
  • 05 May 2022 Adverse event data from a phase II/III trial in COVID-2019 infections released by Medicago
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top